PROTALIX生物療法 PLX 深 滬
已收盤 02-06 16:00:00 美东时间
2.89
-0.020
-0.69%
華盛通- 最 高2.93
- 今 開2.89
- 成交量 255.96万股
- 最 低 2.78
- 昨 收 2.91
- 總市值 2.32亿
- 52周最高 3.10
- 市盈率 靜 78.96
- 換手率 3.18%
- 52周最低 1.32
- 委 比 0.00%
- 總股本 8042.12万
- 歷史最高 77.00
- 量 比 0.96
- 振 幅 5.15%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026If approved by
01-30 22:51
CHMP Recommends Approval of New Elfabrio Dosing Regimen for Protalix BioTherapeutics
CHMP Recommends Approval of New Elfabrio Dosing Regimen for Protalix BioTherapeutics Protalix BioTherapeutics Inc. and Chiesi Global Rare Diseases announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommendin
01-30 22:48
Protalix Bets on Gout and Rare Kidney Diseases as It Eyes New Drug Launches in 2026
Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs,
01-05 19:55
Protalix BioTherapeutics Letter to Stockholders
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercia...
01-05 19:50
Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indicationsProtalix is granted an
2025-12-17 19:53
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications ...
2025-12-17 19:50
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
Protalix BioTherapeutics Q3 EPS $0.03 Misses $0.06 Estimate, Sales $17.673M Miss $17.866M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 45.45 percent. This is unchanged from the same period last year. The company
2025-11-13 19:51
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Protalix Seeks EMA Re-examination for Elfabrio Dosing
Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTher...
2025-11-04 06:10
